Which companies are Komipharm International's closest peers?

The cockpit's peer set: Shanghai Obio Technology (Group) (688238.SS), Steminent Biotherapeutics (7729.TWO), Shattuck Labs (STTK), TaiMed Biologics (4147.TWO), Eupraxia Pharmaceuticals (EPRX.TO), Medigen Vaccine Biologics (6547.TWO), Jacobio Pharmaceuticals (1167.HK), Shanghai ZJ Bio-Tech (688317.SS).

Is Komipharm International expensive compared with its peers?

On ev / sales it trades at 12.1× against a peer median of 10.7×, 7th most expensive of 16 in its peer set.

How has Komipharm International stock performed?

Over six months to 6 Nov 2026 the shares returned -12.0% against -5.3% for the median peer; over one year +38.4%.

← CockpitCompetitor Analysis › 041960.KS Komipharm International Co., LtdOpen in the cockpit ↗

Komipharm International Co., Ltd041960.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Momentum leader 80

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$460M

US dollars, full cap

Free float

59%

of shares outstanding

$/day

$2.00M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-4.6 pp

WACC 5.4%

Hurdle

n/a

no reverse DCF

Close · KRW₩8,550

1D-4.5%

1W-5.7%

1M-22.3%

3M+15.5%

6M-12.0%

YTD+21.8%

1Y+38.4%

ATR %6.3%

52w lowhigh28.1% off high

What Komipharm International does

Employees: 172

Komipharm International at a glance

Size Komipharm International (041960.KS) is a South Korea Health Care company (Biotechnology) with a market value of $460M, the 351st largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩8,550 on 6 Nov 2026.

Performance Over six months the shares fell 12.0%, against -5.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 3.3% over the last twelve months (peer median +5.4%); the operating margin is 1.9% (peer median -15.6%).

Valuation It trades at 12.1× enterprise value to sales against a peer median of 10.7× (7th most expensive of 16).

Capital Return on invested capital runs 4.6 points below its cost of capital (5.4% WACC).

Relative performance

Six months, rebased to 100: Komipharm International against the median of its 20 peers (local-currency closes).

Komipharm International financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₩53.0B	₩52.5B	₩58.8B	₩42.6B	₩39.8B
Revenue growth	—	-11%	+38%	+7%	—
Gross profit	₩17.4B	₩15.9B	₩20.4B	₩11.0B	₩9.55B
EBITDA	₩3.84B	₩2.92B	₩8.37B	-₩2.74B	-₩438M
Net income	-₩2.58B	-₩7.21B	₩13.1B	-₩3.98B	-₩6.51B
Free cash flow	-₩2.42B	-₩3.71B	₩7.80B	-₩3.44B	-₩2.66B
Capital expenditure	₩4.70B	₩4.47B	₩3.98B	₩1.13B	₩1.07B
Total debt	₩41.3B	₩40.7B	₩43.8B	₩45.1B	₩38.1B

Quarterly statements and history in the cockpit →

Komipharm International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Komipharm International is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Komipharm International is the large dot.

Komipharm International competitors and peer comparison

How Komipharm International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Komipharm International against its 20 peers (data as of 6 Nov 2026)
Measure	041960.KS	Peer median	Rank in peer set
1-month return	-22.3%	-13.2%	5th lowest of 21
6-month return	-12.0%	-5.3%	8th lowest of 20
Distance from 52-week high	-28.1%	-35.3%	6th highest of 21
Revenue growth (TTM)	-3.3%	+5.4%	7th lowest of 16
Operating margin	1.9%	-15.6%	6th highest of 16
EV / Sales	12.1×	10.7×	7th most expensive of 16
ROIC minus cost of capital	-4.6 pp	-10.2 pp	4th highest of 17
Net debt / EBITDA	3.6×	-1.8×	most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Komipharm International 041960.KS	South Korea	$460M	-12%	-3%	2%	12.1×	n/a	n/a
Shanghai Obio Technology (Group) 688238.SS	China	$462M	-4%	+20%	-79%	11.4×	n/a	n/a
Steminent Biotherapeutics 7729.TWO	Taiwan	$458M	+139%	n/a	n/a	n/a	n/a	n/a
Shattuck Labs STTK	United States	$464M	-33%	-67%	-5,571%	258.1×	n/a	n/a
TaiMed Biologics 4147.TWO	Taiwan	$454M	+10%	+4%	-30%	22.4×	31.8%	-3.3%
Eupraxia Pharmaceuticals EPRX.TO	Canada	$466M	-5%	n/a	n/a	n/a	n/a	n/a
Medigen Vaccine Biologics 6547.TWO	Taiwan	$467M	-5%	+44%	10%	18.0×	n/a	n/a
Jacobio Pharmaceuticals 1167.HK	Hong Kong	$468M	-27%	+286%	68%	2.5×	-14.9%	-36.1%
Shanghai ZJ Bio-Tech 688317.SS	China	$468M	-16%	-18%	-75%	5.2×	6.0%	-62.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HK	Hong Kong	$469M	-13%	n/a	n/a	n/a	n/a	n/a
Qingdao Vland Biotech 603739.SS	China	$450M	-21%	+5%	7%	2.3×	18.2%	+7.3%
Shanghai Shen Lian Biomedical 688098.SS	China	$444M	-18%	-17%	-16%	12.1×	n/a	n/a
Wuhan Hiteck Biological Pharma 300683.SZ	China	$443M	-36%	-30%	-27%	5.9×	n/a	n/a
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	8,168.1×	n/a	n/a
TenNor Therapeutics Suzhou 6872.HK	Hong Kong	$440M	n/a	n/a	n/a	n/a	n/a	n/a
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%
Ever Supreme Bio Technology 6712.TWO	Taiwan	$439M	+9%	+13%	47%	12.7×	5.8%	+70.5%
Hubei Goto Biopharm 300966.SZ	China	$427M	-7%	+6%	-10%	6.4×	n/a	n/a
EirGenix 6589.TW	Taiwan	$427M	+2%	+27%	-71%	10.7×	n/a	n/a
Polynovo PNV.AX	Australia	$426M	-12%	+13%	5%	4.2×	53.3%	+37.6%

Questions

Which companies are Komipharm International's closest peers?: The cockpit's peer set: Shanghai Obio Technology (Group) (688238.SS), Steminent Biotherapeutics (7729.TWO), Shattuck Labs (STTK), TaiMed Biologics (4147.TWO), Eupraxia Pharmaceuticals (EPRX.TO), Medigen Vaccine Biologics (6547.TWO), Jacobio Pharmaceuticals (1167.HK), Shanghai ZJ Bio-Tech (688317.SS).
Is Komipharm International expensive compared with its peers?: On ev / sales it trades at 12.1× against a peer median of 10.7×, 7th most expensive of 16 in its peer set.
How has Komipharm International stock performed?: Over six months to 6 Nov 2026 the shares returned -12.0% against -5.3% for the median peer; over one year +38.4%.